The American Journal of Medicine
Volume 119, Issue 10 , Pages 812-819 , October 2006

Metabolic Syndrome and Risk of Cardiovascular Disease: A Meta-Analysis

  • Andrea Galassi, MD

      Affiliations

    • Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, La
    • ,
  • Kristi Reynolds, PhD, MPH

      Affiliations

    • Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, La
    • Corresponding Author InformationRequests for reprints should be addressed to Kristi Reynolds, PhD, MPH, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, 1430 Tulane Avenue SL-18, New Orleans, LA 70112.
    • ,
  • Jiang He, MD, PhD

      Affiliations

    • Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, La
    • Department of Medicine, Tulane University School of Medicine, New Orleans, La.

References 

  1. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  2. Trevisan M, Liu J, Bashas FB, Menotti A. Syndrome X and mortality: a population based study; risk factor and life expectancy research group. Am J Epidemiol. 1998;148:958–966
  3. Wilson PW, Kannel WB, Silbershatz H, D’Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104–1109
  4. Gray RS, Fabsitz RR, Cowan LD, et al. Risk factor clustering in the insulin resistance syndrome (The strong heart study). Am J Epidemiol. 1988;148:869–878
  5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  6. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. World Health Organization. Available at: http://whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf. Accessed October 19, 2004.
  7. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444–2449
  8. Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of metabolic syndrome and its relation to all cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164:1066–1076
  9. Malik S, Wong D, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and all causes in United Stated adults. Circulation. 2004;110:1245–1250
  10. Sattar N, Graw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–419
  11. Katzmarzyk PT, Church TS, Blair SN. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med. 2004;164:1092–1097
  12. Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes. 2004;53:1068–1073
  13. Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women’s Ischemia Syndrome Evaluation (WISE) study. Circulation. 2004;109(6):706–713
  14. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716
  15. Onat A, Ceyhan K, Basar O, et al. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis. 2002;165:285–292
  16. Schillaci G, Pirro M, Vaudo G, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol. 2004;19(43):1817–1822
  17. Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care. 2003;26:861–867
  18. Rutter KM, Meigs JB, Sullivan ML, et al. C-Reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring study. Circulation. 2004;110:380–385
  19. Hunt KJ, Resendez RG, Williams K, et al. National cholesterol education program versus world health organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart study. Circulation. 2004;110:1251–1257
  20. Anderson JL. Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease?. Cardiology. 2004;101:185–193
  21. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study. Diabetes Care. 2005;28:385–390
  22. Gimeno Orna JA, Lou Arnal LM, Molinero Herguedas E, et al. Metabolic syndrome as a cardiovascular risk factor in patients with type 2 diabetes. [Spanish] Rev Esp Cardiol. 2004;57:507–513
  23. Bruno G. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes (The Casale Monferrato Study). Diabetes Care. 2004;27:2689–2694
  24. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689
  25. Bonora E, Targher G, Formentini G, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects (Prospective data from the Verona Diabetes Complications Study). Diabet Med. 2004;21:52–58
  26. Bonora E, Kiechl S, Willeit J, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care. 2003;26:1251–1257
  27. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-cause: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis. 2004;173:309–314
  28. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004;93:136–141
  29. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  30. Begg CB. Publication Bias. In:  Cooper H,  Hedges LF editor. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994;p. 399–409
  31. Ruige JB, Assendelft WJ, Dekker JM, et al. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation. 1998;97:996–1001
  32. Diercks GF, van Boven AJ, Jillege JL, et al. The importance of microalbuminuria as a cardiovascular risk indicator: a review. Can J Cardiol. 2002;18:525–535
  33. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442–443
  34. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237–252
  35. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available at: www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf. Accessed November 18, 2005.

 Supported in part by grant number K12HD43451 from the National Institutes of Health to Dr. Reynolds.

PII: S0002-9343(06)00280-4

doi: 10.1016/j.amjmed.2006.02.031

The American Journal of Medicine
Volume 119, Issue 10 , Pages 812-819 , October 2006

Article Tools

* Image Usage & Resolution